Leo Pharma's eczema drug for adolescents meets phase III trial targets
The drug Adtralza, which is developed by Leo Pharma, has reached both its primary and secondary endpoints after a 16-week phase III trial testing the eczema treatment in patients with moderate-to-severe atopic dermatitis.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY DANIEL PEDERSEN
At the 2021 Fall Clinical Dermatology Conference, held virtually and from Las Vegas, pharmaceutical company Leo Pharma presented data from a new trial of its antibody treatment tralokinumab, sold under the brand name Adtralza, which is approved in the EU, the UK and Canada as a treatment for adults with moderate-to-severe atopic dermatitis.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Leo Pharma strongly criticizes Danish Medicines Council
For subscribers
